Allakos secures $10 mln
Biotechnology company Allakos has secured an additional $10 million investment from current investors to fund the development of an additional therapeutic antibody. All of the company's current investors participated including Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
30 September 2014•4 mins read
